CHARACTERIZATION OF NAG EXPRESSION AND FUNCTIONS

NAG 表达和功能的表征

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The focus of this proposal is to understand the molecular and cellular functions of neuroblastoma amplified gene product (NAG), an uncharacterized protein with interesting associations to tumorigenesis, inflammation, and development. The NAG gene is co-amplified with MYCN in neuroblastoma cells; however its expression has been correlated with better prognosis in patients with neuroblastoma. NAG also has been shown to interact with interleukin-1 receptor antagonist, a known anti-inflammatory molecule. In C. elegans NAG expression is important for normal development and has been shown to play a role in nonsense-mediated mRNA decay. By understanding how NAG acts to regulate cellular processes, an understanding of how its expression can affect disease processes such as those associated with cancer and inflammatory autoimmune diseases will be appreciated. Our basic hypothesis is that NAG exists as multiple forms which differentially impact cellular processes and development. To understand the impact of these forms on cellular processes and development, we propose to characterize the expression of NAG isoforms in multiple cell types. We anticipate that different patterns of NAG isoforms will be expressed in these different cell types and that the NAG isoforms will have shared and unique functions important for cellular processes characteristic of the tissue system from which those cells are derived. Additionally, we will develop a C. elegans system to study the NAG homologue. We anticipate the NAG homologue expressed in C. elegans will share basic functions analogous to the vertebrate NAG protein.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 该提案的重点是了解神经母细胞瘤扩增基因产物(NAG)的分子和细胞功能,NAG是一种与肿瘤发生,炎症和发展有有趣关联的未表征蛋白质。 NAG基因在神经母细胞瘤细胞中与MYCN共扩增;然而,其表达与神经母细胞瘤患者的良好预后相关。 NAG还显示与白细胞介素-1受体拮抗剂(一种已知的抗炎分子)相互作用。 In C.线虫NAG表达对于正常发育是重要的,并且已经显示在无义介导的mRNA衰减中起作用。 通过了解NAG如何调节细胞过程,了解其表达如何影响疾病过程,如与癌症和炎性自身免疫性疾病相关的疾病过程,将受到赞赏。 我们的基本假设是NAG以多种形式存在,这些形式对细胞过程和发育有不同的影响。 为了了解这些形式对细胞过程和发育的影响,我们建议在多种细胞类型中表征NAG亚型的表达。 我们预期不同模式的NAG同种型将在这些不同的细胞类型中表达,并且NAG同种型将具有对于那些细胞所来源的组织系统的细胞过程特征重要的共享和独特的功能。 此外,我们将开发一个C。elegans系统来研究NAG同源物。 我们预期在C.线虫将共享与脊椎动物NAG蛋白类似的基本功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CARLA J GUTHRIDGE其他文献

CARLA J GUTHRIDGE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CARLA J GUTHRIDGE', 18)}}的其他基金

RESEARCH OPPORTUNITY AWARD - CHARACTERIZATION OF NAG EXPRESSION AND FUNCTIONS
研究机会奖 - NAG 表达和功能的表征
  • 批准号:
    8167527
  • 财政年份:
    2010
  • 资助金额:
    $ 10.84万
  • 项目类别:
CHARACTERIZATION OF NAG EXPRESSION AND FUNCTIONS
NAG 表达和功能的表征
  • 批准号:
    7960001
  • 财政年份:
    2009
  • 资助金额:
    $ 10.84万
  • 项目类别:
CHARACTERIZATION OF NAG EXPRESSION AND FUNCTIONS
NAG 表达和功能的表征
  • 批准号:
    7610256
  • 财政年份:
    2007
  • 资助金额:
    $ 10.84万
  • 项目类别:
ANALYSIS OF ICIL-1RA1 AND NAG INTERACTIONS
ICIL-1RA1 和 NAG 相互作用的分析
  • 批准号:
    7381640
  • 财政年份:
    2006
  • 资助金额:
    $ 10.84万
  • 项目类别:
ANALYSIS OF ICIL-1RA1 AND NAG INTERACTIONS
ICIL-1RA1 和 NAG 相互作用的分析
  • 批准号:
    7170877
  • 财政年份:
    2005
  • 资助金额:
    $ 10.84万
  • 项目类别:
EQUIPMENT FOR CAMERON UNIVERSITY
卡梅伦大学设备
  • 批准号:
    7170899
  • 财政年份:
    2005
  • 资助金额:
    $ 10.84万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 10.84万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 10.84万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 10.84万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 10.84万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 10.84万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 10.84万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 10.84万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 10.84万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 10.84万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 10.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了